Who Qualifies for GLP-1 Medication for Weight Loss?

Who Qualifies for GLP-1 Medication for Weight Loss: The Short Answer

GLP-1-based medications for weight management are prescription treatments that require a clinical evaluation before they can be prescribed. In general, FDA-approved weight-management medications such as Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated for adults with obesity or adults with overweight and at least one weight-related health condition. Eligibility also depends on the specific medication, indication, medical history, contraindications, and overall benefit-risk assessment. At Lttl, a licensed clinician reviews your complete health history, current medications, relevant contraindications, and treatment goals before making any prescribing decision. The criteria below reflect general clinical guidance, not a self-assessment checklist. Whether GLP-1 therapy is appropriate for you is a medical determination, not a calculation.

Common Eligibility Factors Clinicians Consider

Clinicians evaluating a patient for GLP-1-based weight management therapy consider multiple factors, and their importance varies by individual. The following are general clinical considerations rather than a self-assessment checklist or guarantee of eligibility.

Factor	What Clinicians Typically Look For
BMI	For FDA-approved chronic weight-management medications, adults with obesity may meet the weight-based indication, while adults with overweight generally must also have at least one weight-related comorbid condition. Eligibility depends on the specific medication and the patient's complete clinical profile.
Weight-related comorbidities	Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
Treatment history	Prior weight loss attempts, including lifestyle interventions and previous medications
Treatment goals	Degree of weight loss sought, metabolic health objectives, and patient's timeline expectations
Age and product indication	Semaglutide (Wegovy) is approved for adults and adolescents aged 12 and older; Tirzepatide (Zepbound) is currently approved for adults only
Overall benefit-risk assessment	Weighing the potential clinical benefit against individual contraindications, comorbidities, and patient preference
Cardiovascular history	Semaglutide (Wegovy) has an additional FDA-approved indication for reducing cardiovascular event risk in adults with obesity or overweight and established cardiovascular disease

These factors are considered together, not in isolation. A patient who meets the BMI threshold but has a contraindication may not be appropriate for treatment. Patients who do not meet the FDA-labeled weight criteria may still benefit from a broader clinical evaluation of their metabolic health and weight-related concerns, although that does not necessarily mean a GLP-1-based medication is indicated. The table above only describes some common considerations; it doesn't replace the evaluation.

Medical History That May Affect GLP-1 Treatment

Certain medical history factors require careful review before starting GLP-1 therapy. None of the following are automatic disqualifiers in every case, but all of them are relevant to a thorough eligibility assessment.

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Wegovy (semaglutide) and Zepbound (tirzepatide) are contraindicated in patients with a personal or family history of MTC or in patients with MEN2.

History of pancreatitis. GLP-1 medications have been associated with pancreatitis risk. A prior episode (acute or chronic) requires careful evaluation and discussion of individual risk before treatment can be considered.

Gallbladder disease or history of gallstones. Both rapid weight loss and GLP-1 therapy have been independently associated with increased risk of gallbladder events. Patients with relevant history should discuss this with their clinician.

Gastroparesis or severe gastrointestinal disease. GLP-1-based therapies delay gastric emptying and may cause gastrointestinal adverse reactions. Wegovy and Zepbound are not recommended in patients with severe gastroparesis.

Renal disease or risk of volume depletion. Gastrointestinal adverse effects such as nausea, vomiting, and diarrhea can lead to dehydration and acute kidney injury. Renal function may require monitoring when symptoms could lead to significant volume depletion, particularly in patients with underlying renal disease.

Diabetic retinopathy. Patients with type 2 diabetes and a history of diabetic retinopathy should be aware that rapid improvements in blood sugar control have been associated with early worsening of retinopathy in some cases. Ophthalmologic monitoring may be appropriate.

Pregnancy, planned pregnancy, or breastfeeding. Weight loss is not recommended during pregnancy, and these medications should be discontinued when pregnancy is recognized. Product-specific recommendations should be followed when planning pregnancy. For Wegovy (semaglutide), the prescribing information recommends discontinuing treatment at least 2 months before a planned pregnancy because of semaglutide's long half-life. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss treatment with their clinician.

History of significant eating disorders. The pronounced appetite-suppressing effects of GLP-1 medications may complicate recovery in patients with a history of restrictive eating. Individual clinical assessment of appropriateness is especially important in this population.

Medication and Supplement Review

A complete and accurate medication list is one of the most important things you can bring to a GLP-1 eligibility assessment. Several categories of medication require specific attention.

Blood sugar-lowering medications. Patients taking insulin or sulfonylureas alongside a GLP-1 medication face an increased risk of hypoglycemia. Dose adjustments to existing diabetes medications are often needed when starting GLP-1 therapy, and those adjustments should be clinician-directed rather than self-managed.

Oral medications with narrow therapeutic windows. GLP-1 medications slow gastric emptying, which can affect the absorption timing and rate of some oral drugs. Medications where consistent absorption matters may require additional monitoring or timing adjustments. Your clinician needs to know about these before prescribing.

Other GLP-1-based medications. Wegovy should not be used with other semaglutide-containing products or other GLP-1 receptor agonists. Zepbound should not be coadministered with other tirzepatide-containing products or GLP-1 receptor agonists. Tell your clinician about all prescription, compounded, and nonprescription products you are using before starting treatment.

Supplements. Tell your clinician about all vitamins, supplements, and over-the-counter products you use. Products that may affect blood glucose, appetite, gastrointestinal symptoms, or medication absorption should be reviewed as part of the overall medication assessment.

The goal of a medication review isn't to find a reason to deny treatment; it's to make sure that if treatment is prescribed, it's prescribed safely and that any necessary adjustments to your existing regimen are made before you start.

BMI Is Not the Only Consideration

BMI is a useful population-level screening tool, but it has well-documented limitations as a measure of individual health. It doesn't distinguish between fat mass and lean mass, doesn't account for how fat is distributed in the body, and can misclassify both risk and health status across different body types and ethnic backgrounds.

In clinical practice, this matters in a few specific ways. A patient with a BMI just below 30 who carries significant visceral fat, has elevated triglycerides, and a family history of type 2 diabetes may face meaningfully higher metabolic risk than a BMI-matched number suggests. Conversely, a patient with a higher BMI who is otherwise metabolically healthy may have a different risk profile than the number alone implies.

BMI is one component of determining whether a patient meets the indicated criteria for weight-management pharmacotherapy. The prescribing decision also considers comorbidities, treatment history, cardiovascular and metabolic risk, contraindications, medication history, treatment goals, and the overall balance of potential benefits and risks.

What Happens During a GLP-1 Eligibility Assessment?

At Lttl, the eligibility process is designed to be straightforward for patients while still meeting the clinical standard that a GLP-1 prescription requires.

Step 1: Complete the intake assessment. The process starts with a detailed health questionnaire that covers your medical history, current medications and supplements, relevant family history, previous weight loss attempts, and your treatment goals. This typically takes around two minutes and is where the clinical picture begins to take shape. Be honest and open: Your answers directly affect what the reviewing clinician sees, how they evaluate your case, and how they can provide the best treatment for your needs.

Step 2: Clinician review. A licensed clinician reviews your intake individually. This isn't an automated approval process. A real clinician reads your history, evaluates your eligibility against current clinical criteria and contraindications, and makes a prescribing decision based on your specific profile. If your intake raises questions that require clarification or additional information, your clinician will follow up before making a determination.

Step 3: Lab work, if needed. Depending on your medical history, medications, symptoms, and available health information, the clinician may determine that laboratory testing is appropriate before or during treatment. Testing should be individualized rather than considered universally required for GLP-1-based therapy. If you have recent results from your primary care provider, those can often be submitted directly.

Step 4: Treatment plan or alternative guidance. If GLP-1-based therapy is appropriate for you, your clinician will develop an individualized treatment plan that addresses medication selection, appropriate initiation or transition, dose escalation, monitoring, and follow-up. If it isn't appropriate, you'll receive a clear explanation of why and, where possible, guidance on alternatives or next steps. Lttl does not approve every intake: that's part of what makes the process clinically legitimate.

What to have ready: your current medication list (including supplements), any relevant recent lab results, a list of significant medical history (including surgeries and chronic conditions), and a clear sense of your weight loss goals and timeline.

Frequently Asked Questions

I'm Overweight, but Not Obese. Can I Still Qualify?

Possibly. The FDA-approved indications for semaglutide (Wegovy) and tirzepatide (Zepbound) include adults with a BMI of 27 or higher (below the obesity threshold), if they have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. If you fall into that category, a clinical evaluation is the right next step. If you don't meet either the BMI or comorbidity criteria, GLP-1 medications for weight management may not be clinically indicated, and a clinician will tell you that during the assessment.

Do I Need to Have Type 2 Diabetes to Qualify?

No. Type 2 diabetes is not required to be eligible for Wegovy (semaglutide) or Zepbound (tirzepatide) for weight management. These products have weight-management indications that are distinct from the diabetes indications of other products containing the same active ingredients. Ozempic contains semaglutide and Mounjaro contains tirzepatide, but each brand has its own FDA-approved indications, dosing, and prescribing information.

I've Tried Other Weight Loss Medications Before. Does That Affect Eligibility?

Prior use of weight loss medications is part of the clinical history your clinician reviews, but it doesn't automatically disqualify you. Treatment history helps inform the prescribing decision, including which medication may be appropriate and how treatment should be initiated or transitioned. Previous use of a GLP-1-based medication, including the medication, dose, timing of the last dose, response, and any adverse effects, should be reviewed before a new regimen is selected. If you had significant side effects or inadequate response with a previous GLP-1 medication, that's relevant context the clinician needs to know.

Is There an Age Limit for GLP-1 Weight Management Medications?

Current FDA approvals cover adults for both semaglutide (Wegovy) and tirzepatide (Zepbound). Wegovy has also been approved for adolescents aged 12 and older with obesity. The prescribing information does not specify a general upper age cutoff for these adult indications. Treatment decisions in older adults should be individualized based on overall health, comorbidities, concomitant medications, tolerability, nutritional status, and the expected benefits and risks of treatment. A clinician will factor age and overall health status into the eligibility assessment.

Can I Switch From One GLP-1 Medication to Another Through Lttl?

Patients considering a transition between semaglutide and tirzepatide should discuss it with their clinician. These medications should not be used concurrently for weight management, and decisions about when and how to transition should be individualized based on the current medication, dose, timing of the last dose, treatment response, tolerability, and relevant medical history. If you're switching because of side effects, insufficient response, or a change in your goals, that context is helpful for the clinician to have before making a recommendation.

Bibliography

• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• U.S. Food and Drug Administration. (2024). Highlights of prescribing information: Wegovy (semaglutide) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• U.S. Food and Drug Administration. (2025). Highlights of prescribing information: Zepbound (tirzepatide) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
• Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boule, N., Boyling, E., Brown, J., Calam, B., Clarke, C., Crowshoe, L., Divalentino, D., Forhan, M., Freedhoff, Y., Gagner, M.,... Wicklum, S. (2020). Obesity in adults: A clinical practice guideline. CMAJ, 192(31), E875-E891. https://www.cmaj.ca/content/192/31/E875
• Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. https://pubmed.ncbi.nlm.nih.gov/35015037/